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Introduction
Around 350,000 new breast cancer cases are detected in 
Europe every year. Because of the progress made in the 
treatment of this cancer, mortality in patients is now 
increasingly linked to the occurrence of distant meta-
stases. Certain organs are favored sites for circulating 
cancer cells to develop metastases, and this can only arise 
through a permissive microenvironment in the target 
tissue that facilitates tumor growth [1]. In this respect, 
breast cancer is prone to metastasize to bone: around 70 
to 80% of patients with advanced disease exhibit bone 
metastases [2]. Th   ese skeletal lesions can be fatal or may 
rapidly impede the quality of life of patients by causing 
pathological fractures, hypercalcemia, nerve compression 
and loss of mobility [2]. Most of these patients will also 
experience substantial, life-altering cancer-induced bone 
pain. Th  ere is therefore a need to better understand 
molecular mechanisms associated with cancer-induced 
bone diseases in order to improve existing therapies and/
or develop new targeted therapies.
Here, I provide an overview of current research and 
insights into the cellular and molecular events that 
mediate bone metastasis formation and discuss the evi-
dence that some of these events could stand as thera-
peutic targets to treat skeletal lesions in breast cancer.
Pathogenesis of breast cancer bone metastases
Once metastatic breast cancer cells are in the bone 
marrow, they do not, on their own, destroy bone. Instead, 
they alter the functions of bone-resorbing (osteoclasts) 
and bone-forming cells (osteoblasts) and hijack signals 
coming from the bone matrix, thereby disrupting 
physiological bone remodeling [2,3]. Indeed, there is a 
‘vicious cycle’ whereby metastatic cells residing in the 
bone marrow secrete factors that stimulate osteoclast-
mediated bone resorption and growth factors released 
from resorbed bone stimulate tumor growth [2]. Breast 
cancer cells may also interact with preosteoclasts, result-
ing in direct stimulation of osteoclast diﬀ  erentiation and 
maturation [4]. Furthermore, breast cancer cells secrete 
factors that inhibit osteoblast diﬀ  erentiation and activity 
[2,3]. Th   eir interaction with osteoblasts also induces the 
release of cytokines that promote tumor growth [4]. 
Taken together, this leads to an imbalance between bone 
resorption and bone formation, resulting in enhanced 
skeletal destruction and, as a consequence of osteolysis, 
occurrence of pathological fractures (Figure 1).
Several molecules that are produced by breast cancer 
cells - for example, parathyroid hormone-related protein, 
interleukins (IL-6, IL-8, and IL-11), cytokines (macro-
phage colony stimulating factor (M-CSF)) and prosta-
glandins - stimulate osteoclast activity through the 
activa  tion of the receptor activator of nuclear factor-kB 
ligand (RANKL)/RANK pathway, which is the primary 
mediator of osteoclast-mediated bone resorption [3,5]. 
Breast cancer cells may also directly stimulate 
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preosteoclasts through the Jagged1-Notch pathway [4]. 
In addition, breast cancer cells secrete activin A (a 
member of the transforming growth factor (TGF)-β 
super  family of growth factors), noggin (a bone morpho-
genetic protein (BMP) antagonist) and dickkopf-1 
(DKK-1; a Wingless/int (Wnt) protein antagonist), all of 
them inhibiting osteoblast diﬀ  erentiation [3,6]. As bone 
is resorbed, growth factors (for example, TGF-β and 
insulin-like growth factor-I) stored in the bone matrix are 
then liberated and stimulate breast cancer cell 
proliferation, providing a supportive niche for tumor 
growth (Figure 1).
Th  e realization that normal cells in the bone micro-
environment support the development of skeletal lesions 
has led to the use of bisphosphonates, as inhibitors of 
osteoclast-mediated bone resorption, in the treatment of 
patients with bone metastases [2]. Nitrogen-containing 
bisphosphonates speciﬁ   cally inhibit osteoclast farnesyl 
pyrophosphate synthase activity, a key enzyme in the 
mevalonate pathway, which causes the inhibition of 
prenylation of small GTPases and the subsequent 
Figure 1. In bone, breast cancer cells secrete diff  erent factors that stimulate osteoclast diff  erentiation and maturation through the 
activation of the RANKL/RANK or the Jagged1/Notch signaling pathways. Then, integrin, Src and cathepsin K play an essential role in the 
bone-resorbing activity of mature osteoclasts. In addition, breast cancer cells secrete components (DKK-1, activin A) that inhibit osteoblast 
diff  erentiation. This leads to enhanced bone destruction and, as a consequence, to the release of bone derived-factors (TGF-β) that stimulate tumor 
growth. Moreover, CXCL-12 produced by osteoblasts promotes the recruitment and survival of CXCR4-expressing breast cancer cells. There is 
therefore a ‘vicious cycle’ (depicted by the large blue arrows) whereby metastatic cells stimulate osteoclast-mediated bone resorption and growth 
factors released from resorbed bone stimulate tumor growth. Red boxes highlight components that are attractive therapeutic targets, some of 
which are in clinical development. The drawings were produced using Servier Medical Art [55]. Abbreviations: CXCL-12, C-X-C motif chemokine 12; 
CXCR4, C-X-C chemokine receptor type 4; DKK-1, dickkopf-1; FPPS, farnesyl pyrophosphate synthase; IL, interleukin; M-CSF, macrophage-colony 
stimulating factor; PGE2, prostaglandin E2; PTHrP, parathyroid hormone-related peptide; RANK, receptor activator of nuclear factor kB; RANKL, RANK 
ligand; Src, proto-oncogene tyrosine-protein kinase; TGF-β, transforming growth factor-β.
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Page 2 of 9inactivation of osteoclasts. In addition to inhibition of 
osteoclast activation and function, a growing body of 
preclinical evidence indicates that these nitrogen-
contain  ing bisphosphonates exert direct and/or indirect 
antitumor eﬀ  ects.  Th  ese antiresorptive and antitumor 
eﬀ  ects of bisphosphonates have been recently reviewed 
[7] and, therefore, will not be discussed here. Th  e 
following is a review of factors that are promising 
molecular bone-targeted therapies or will be likely targets 
for future therapeutic intervention to restore bone 
remodeling and suppress tumor growth.
Novel targets to inhibit osteoclast-mediated bone 
resorption
Factors that promote osteoclast formation (RANK/
RANKL), activation (integrin, c-Src) and function (cathep-
sin K) represent promising therapeutic targets for 
inhibition of pathological bone resorption.
RANKL/RANK
RANKL, RANK and osteoprotegerin (OPG) are key 
regulators of osteoclast-mediated bone resorption [5]. 
RANKL is a transmembrane protein expressed on the 
surface of osteoblasts that can be cleaved as a soluble 
form by proteases [5]. Both the membrane-bound and 
soluble forms of RANKL attach to RANK, a receptor on 
the cell surface of osteoclast precursors, to stimulate 
osteoclastogenesis [5]. Conversely, OPG is a soluble 
RANKL inhibitor produced by osteoblasts that inhibits 
RANKL/RANK interaction [5]. Hence, the balance 
between RANKL and OPG regulates the process of bone 
resorption, and the disruption of this balance is observed 
in many cancers, including breast cancer [3].
Th  ere is a growing body of evidence that RANK/
RANKL plays a critical role in the expansion of tumor 
cells in bone [3,8]. As a consequence, OPG is capable of 
inhibiting bone destruction and reducing skeletal tumor 
burden in animal models of breast cancer bone meta-
stasis [3,8]. Th  is reduction in tumor burden is likely 
related to OPG inhibition of osteoclast-mediated bone 
resorption because OPG does not aﬀ  ect tumor growth in 
soft tissues [8]. However, tumor-derived matrix metallo-
proteinase (MMP)-7 and membrane type 1 matrix metallo-
proteinase (MT1-MMP) both function as sheddases that 
release RANKL conﬁ  ned on the osteoblast surface, and 
the resulting soluble form of RANKL can stimulate the 
migration of RANK-expressing breast cancer cells in a 
manner that is inhibited by OPG [5,8,9]. Moreover, 
RANK and RANKL are expressed in the normal 
mammary epithelium of mouse mammary tumor virus 
(MMTV)-neu transgenic mice, a spontaneous mammary 
tumor model, and the selective pharmacological inhibi-
tion of RANKL with RANK-Fc reduces mammary tumor 
development in these transgenic mice [10].
Denosumab, a fully human monoclonal antibody directed 
against RANKL, is currently in clinical development for 
use in postmenopausal osteoporosis and cancer-induced 
bone diseases, including metastatic breast cancer 
(Table 1) [8]. Denosumab is superior to bisphosphonate 
zoledronate in delaying time to ﬁ   rst and subsequent 
skeletal-related events in breast cancer patients with 
bone metastases, demonstrating its potency as an anti-
resorptive agent [11]. However, no diﬀ  erence in overall 
survival is observed between patients treated with 
denosumab or zoledronate [11]. Importantly, denosumab 
induced an 86% tumor response rate in patients with 
giant cell tumor of bone; this type of tumor consists of 
RANK-expressing osteoclast-like giant cells and mono-
nuclear (stromal) cells that express RANKL [12]. 
Considering the potential role of RANKL on RANK-
expressing breast cancer cells in preclinical models, it will 
be interesting to know whether denosumab could exhibit 
antitumor eﬀ  ects in the clinical setting. In this respect, 
denosumab is being assessed in two large phase III 
clinical trials examining prevention of bone loss in 
women with early breast cancer (Table 1). Th  ese  clinical 
trials will be helpful to determine whether denosumab 
has any antitumor properties.
Integrins
Integrins are a family of cell surface receptors that 
primarily mediate interactions of cells with components 
of the extracellular matrix. Th  ey form heterodimeric 
transmembrane receptors consisting of noncovalently 
associated α and β subunits. Although osteoclasts express 
various integrins, it is now well accepted that avb3 
integrin is a central molecule for osteoclast function [13]. 
It mediates the capacity of the cell to polarize, spread, 
form an actin ring (which surrounds the ruﬄ   ed border), 
and degrade bone. Upon integrin activation, αvβ3 
stimulates an intracellular signaling complex consisting 
of tyrosine kinases c-Src and Syk [13]. Th   e importance of 
αvβ3, c-Src and Syk in osteoclast activity is revealed by 
the knock-out of each of these genes in mice, which leads 
to the development of osteopetrosis because of the lack 
of bone resorption [13]. Th  us, αvβ3, c-Src and Syk 
represent an essential signaling complex in the bone-
resorbing osteoclast, and each member of this complex is 
a candidate therapeutic target.
Th   ere is preclinical evidence that αvβ3 integrin-target-
ing drugs, including peptides (S247, ATN-161, cilengi-
tide) and nonpeptidic small molecules (PSK1404), 
success  fully block osteolysis and tumor growth in animal 
models of bone metastasis [14,15]. Not only are these 
αvβ3 antagonists inhibitory for osteoclast-mediated bone 
resorption, but we have shown that PSK1404 prevents 
bone colonization by αvβ3-expressing human breast 
cancer cells when using a dosing regimen that did not 
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αvβ3 would be particularly promising for the treatment of 
advanced cancers associated with skeletal lesions because 
these drugs could inhibit bone metastasis forma  tion in at 
least two ways: by inhibiting osteoclast-mediated bone 
resorption and by directly targeting cancer cells.
Th   ere are several ongoing clinical trials evaluating the 
anticancer eﬀ   ect of integrin antagonists in advanced 
refractory and metastatic cancers [14,16]. Only a few 
integrin antagonists are being evaluated in breast cancer 
patients with bone metastasis (Table 1). In this context, 
Galapagos announced (December 2010), based on good 
safety results in healthy volunteers, that it plans to initiate 
a phase I clinical trial in cancer patients with the integrin 
antagonist GLPG0187 (an antagonist developed on the 
basis of experimental ﬁ  ndings obtained with PSK1404 
[14]). Another drug in clinical trials, ATN-161 (developed 
by Attenuon), is a non-RGD peptide derived from the 
synergy region of ﬁ  bronectin that binds to αvβ3 and α5β1 
and blocks tumor growth and bone metastasis in animals 
[14]. ATN-161 is being tested in a phase I trial in patients 
with advanced solid tumors [16]. Similarly, IMGN388 
(developed by ImmunoGen, Inc.) is a human IgG1 anti-
αv integrin antibody conjugated to the maytansinoid 
DM4 that is being tested in patients with advanced solid 
tumors, including metastatic breast carcinoma (Table 1). 
Cilengitide (developed by Merck), a RGD-mimetic cyclic 
peptide inhibitor of both αvβ3 and αvβ5 integrins, 
inhibits bone metastasis in animals [15], and is currently 
being tested in patients with glioblastoma and advanced 
solid tumors, including breast cancer (Table 1) [16]. 
Finally, L-000845704 (developed by Merck), an  αvβ3 
integrin non  peptide antagonist, inhibits bone resorption 
in women with postmenopausal osteoporosis [17]. It 
would be interesting to examine the eﬀ  ect of this agent in 
clinical oncology.
c-Src
c-Src belongs to a family of non-receptor tyrosine kinases 
implicated in controlling signal transduction downstream 
of a variety of cell surface receptors, including integrins, 
E-cadherin and tyrosine kinase receptors [18]. It is also 
activated in response to RANKL/RANK interaction in 
osteoclasts after the recruitment of TRAF6 (tumor 
necrosis factor receptor-associated factor 6) to the intra-
cellular domain of RANK to mediate downstream signal-
ing [18]. Th   erefore, c-Src has a central role in osteoclast 
function.
Table 1. Clinical studies of novel bone-targeted therapies in breast cancer
       Trial numberb
Targeta  Agent  Phase  Design, number of patients  and reference
RANKL  Denosumab  III  Randomized, double-blind, multicenter study of denosumab compared with zoledronic acid   NCT00321464
      in the treatment of bone metastases in subjects with advanced breast cancer (n = 2,049)  [11]
  Denosumab  III  Randomised, double-blind, placebo-controlled, multicenter study to determine the   NCT00556374
     treatment  eff  ect of denosumab in subjects with non-metastatic breast cancer receiving   (ongoing)
      aromatase inhibitor therapy (n = 3,400)
  Denosumab  III  Randomised, double-blind, placebo-controlled, multicenter study of denosumab as   NCT01077154
      adjuvant treatment for women with early stage breast cancer at high risk of recurrence   (ongoing)
      (n = 4,500)
Integrin  Cilengitide  I  Dose escalation study of the safety, tolerability and pharmacokinetic properties of the   NCT01276496
      combination of cilengitide and paclitaxel in patients with advanced solid malignancies   (ongoing)
      (n = 32)
  IMGN388  I  A phase I dose-escalation study of IMGN388 in patients with solid tumors (ovary, lung   NCT00721669
      and breast) that are metastatic or unresectable (n = 90)  (ongoing)
c-Src  Saracatinib  II  A randomised, open-label, pilot study to evaluate the safety and eff  ects on bone resorption   NCT00558272
      of AZD0530 in patients with prostate cancer or breast cancer with bone metastases (n = 132)  (ongoing)
  Saracatinib  II  A study of AZD0530 in hormone receptor-negative, metastatic or unresectable, locally   NCT00559507
      advanced breast cancer (n = 41)  (ongoing)
  Dasatinib  I/II  A study of dasatinib in combination with zoledronic acid for the treatment of breast cancer   NCT00566618
      with bone metastasis (n = 55)  (ongoing)
  Dasatinib  II  Studies of two diff  erent schedules of dasatinib (NSC-732517) in bone metastasis   NCT00410813
      predominant metastatic breast cancer (n = 80)  (ongoing)
Cathepsin K  Odanacatib  II  A study to assess the safety, tolerability, and effi   cacy of MK-0822 (cathepsin K inhibitor) in   NCT00399802
      the treatment of women with breast cancer and established bone metastases (n = 45)  [28]
CXCR4  CTCE-9908  I/II  A study to assess the tolerability and safety profi  le of repeated administration of CTCE-9908   [51]
      in patients with advanced metastatic disease (n = 25) who stopped responding to standard 
      treatments or for whom no curative therapy exists (breast cancer, n = 8)
aCXCR4, C-X-C chemokine receptor type 4; RANKL, receptor activator of nuclear factor-kB ligand; c-Src, proto-oncogene non-receptor tyrosine kinase. bData obtained 
from ClinicalTrials.gov [56].
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cancer cells in Src null mice shows that these animals are 
protected from tumor-associated bone destruction 
because Src-defective osteoclasts do not resorb bone 
[19]. In addition, high activation of c-Src frequently 
occurs in cancer cells and the overexpression of a 
dominant negative form of Src in human MDA-MB-231 
breast cancer cells decreases their tumorigenicity and 
their ability to induce lung and bone metastases in 
animals [20,21]. Indeed, Src is critical for the survival and 
outgrowth of breast cancer cells in the bone marrow. Src 
mediates AKT regulation and cancer cell survival res-
ponses to CXCL12 and TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand), two factors that are 
distinctively expressed in the bone metastasis micro-
environment [22]. Preclinical studies also showed that c-
Src inhibitors (CGP76030, AP23451, dasatinib) success-
fully inhibited MDA-MB-231 breast cancer invasion, 
growth and bone metastasis formation in animals 
[18,21,22]. Th  us, c-Src in osteoclasts and cancer cells 
could be a therapeutic target in the clinic.
Several pharmaceutical companies have now advanced 
Src inhibitors as potential therapeutic agents for use in 
bone-related diseases associated with breast cancer 
(Table 1). For example, saracatinib (AZD0530; Astra-
Zeneca), a dual inhibitor of Src/Abl, has been shown to 
decrease levels of bone resorption markers in a phase I 
study in patients with solid tumors [23]. Phase II studies 
are ongoing to evaluate saracatinib eﬀ   ects in patients 
with breast cancer and (bone) metastases (Table 1). 
Similarly, the eﬃ     cacy of dasatinib (an inhibitor of 
multiple tyrosine kinases; Bristol-Myers Squibb), alone or 
in combination with bisphosphonate zoledronate, is 
being tested in patients with breast cancer and bone 
metastases (Table 1). Bosutinib (developed by Pﬁ  zer) is 
another dual inhibitor of Src/Abl that is in clinical 
development [24]. However, there are no clinical studies 
in metastatic bone disease with this drug to date.
Cathepsin K
Cathepsin K is a lysosomal cysteine protease highly 
expressed in osteoclasts that plays a major role in bone 
resorption [3,25]. Bone resorption can be viewed as a 
sequential process where the secretion of protons by 
osteoclasts induces the dissolution of the mineral phase 
and provides an optimal acidic microenvironment for the 
subsequent proteolytic activity of osteoclast-derived 
cathepsin K, enabling degradation of the demineralized 
collagenous matrix [25]. Th   e function of cathepsin K in 
osteoclasts was ﬁ  rst revealed by the ﬁ  nding of a loss-of-
function mutation in the human cathepsin K gene in 
patients with pycnodysostosis, a rare genetic disorder 
characterized by impaired osteoclastic bone resorption 
[25]. Moreover, such a pycnodysostosic phenotype can be 
reproduced in mice in which cathepsin K has been 
genetically ablated [25]. Conversely, overexpression of 
cathepsin K in mice results in increased bone degradation 
[24]. Overall, these ﬁ   ndings indicate that cathepsin K 
plays a key role in osteoclast-mediated bone resorption.
Soon after the discovery that cathepsin K was a major 
cysteine protease in osteoclasts, it was postulated that 
molecules that inhibit cathepsin K activity could serve as 
useful therapeutic agents against diseases associated with 
excessive levels of bone destruction. Moreover, cathepsin 
K inhibitors not only inhibit bone resorption but also 
stimulate bone formation [26]. It has been suggested that 
cathepsin K inhibitors might prevent degradation of 
bone-derived growth factors, allowing their release from 
the bone matrix as biologically active molecules that 
could then stimulate bone formation [26]. Th  us, by 
facilitating bone formation, cathepsin K inhibitors seem 
to have an advantage over other antiresorptive agents in 
the treatment of diseases associated with bone loss.
Pre-clinical data have shown that the cathepsin K 
inhibitor AFG-495 reduced bone destruction and skeletal 
tumor burden in animal models of breast cancer bone 
metastasis [27]. Although breast cancer cells that meta-
stasize to bone express cathepsin K [3,27], this reduction 
of skeletal tumor burden is most probably due to the 
antiresorptive activity of AFG-495 which, in turn, 
deprives breast cancer cells of bone-derived growth 
factors that are required for tumor growth. Th  is  assump-
tion was supported by the observation that AFG-495 
therapy did not inhibit subcutaneous growth of breast 
tumor xenografts at a dosing regimen that did inhibit 
skeletal tumor burden in animals [27]. Th   us, cathepsin K 
inhibitors render the bone a less favorable microenviron-
ment for tumor growth by inhibiting osteoclast-mediated 
bone resorption.
Cathepsin K inhibitors may have some shortcomings 
[25]. For instance, the basic nitrogen-containing cathep-
sin K inhibitor balicatib (AAE-581, Novartis) accumulates 
within acidic subcellular organelles such as lysosomes. 
Th   ese lysosomotropic properties of balicatib result in the 
inhibition of the activity of other cysteine cathepsins 
present in lysosomes, which may cause adverse eﬀ  ects in 
patients. For example, it has been reported in a 12-month 
phase III trial that a small number of patients experienced 
skin adverse eﬀ  ects during balicatib therapy, which led to 
the withdrawal of the inhibitor from human osteoporosis 
clinical trials [25]. Th  is  oﬀ  -target inhibitory activity does 
not occur with odanacatib (MK-0822, Merck), which is a 
promising compound under investigation in clinical trials 
for osteoporosis therapy. Clinical trials of cathepsin K 
inhibitors in oncology are limited to date (Table 1). A 
phase II trial in women with breast cancer and bone 
metastases shows that odanacatib successfully reduces 
bone resorption markers after 4 weeks of treatment [28].
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Th  e realization that osteolytic lesions resulted not only 
from enhanced osteoclast-mediated bone resorption but 
also from inhibition of bone formation led to the 
development of therapeutic strategies aimed at restoring 
osteoblast function.
DKK-1
Th  e Wnt signaling pathway plays a key role in osteo-
blastogenesis. Wnt proteins bind Frizzled receptor family 
members and, in association with low-density lipoprotein 
receptor-related protein (LRP)5/6, trigger downstream 
signaling via β-catenin, which induces activation of diﬀ  er-
ent genes involved in osteoblastogenesis [29]. DKK-1 binds 
to LRP5/6 and blocks the interaction with Wnt-1, resulting 
in b-catenin degradation and inhibition of osteoblast 
diﬀ  erentiation [29]. Elevated levels of DKK-1 were ﬁ  rst 
described in the serum and bone marrow of patients with 
multiple myeloma [30]. Th  e block  ade of DKK-1 using 
neutralizing antibodies resulted in a decrease of both 
osteolysis and skeletal tumor growth in a severe combined 
immunodeﬁ  ciency (SCID)-hu murine model of multiple 
myeloma [31,32]. Moreover, DKK-1 antibody treatment 
led to a signiﬁ  cant increase in osteoblast number, serum 
human osteocalcin level, and trabecular bone, indicating 
that this antibody had bone anabolic eﬀ  ects [31,32]. A 
clinical trial combining the DKK1-neutralizing antibody 
BHQ880 (Novartis) and zoledronate in relapsed/refractory 
myeloma patients is currently ongoing (NCT00741377). 
By contrast, there have been no clinical trials of BHQ880 
in breast cancer to date. Nevertheless, there is some pre-
clinical and clinical evidence that DKK-1 is secreted by 
breast cancer cells that metastasize to bone [33]. In 
addition, breast cancer-derived DKK1 inhibits osteoblasto-
genesis [34]. Further studies are therefore required to 
examine the importance of DKK-1 as a therapeutic target 
for breast cancer bone metastasis.
Sclerostin
Sclerostin is another Wnt inhibitor produced by osteo-
cytes [35]. Sclerostin-neutralizing antibodies have been 
developed to inhibit the binding of sclerostin to the LRP5 
receptor [35]. Clinical ﬁ   ndings demonstrate a strong 
anabolic eﬀ  ect of sclerostin antibody treatment in osteo-
porotic patients [35]. Th  ere is no evidence for a role of 
sclerostin in experimental bone metastasis. Additionally, 
no clinical trials using the sclerostin antibody in cancer-
induced bone diseases have been initiated so far.
Activin A
Activin A is a member of the TGF-β superfamily of 
growth factors that is widely distributed in diﬀ  erent cells 
and tissues [36]. Th  e biological eﬀ  ects of activin A are 
mediated by two transmembrane serine/threonine kinase 
receptors. Activin A binds to Act RII type-II receptor (or 
Act RIIA), which leads to the recruitment, phosphory-
lation and activation of ActRIB or activin-like kinase 
(ALK)4 type I receptors [36]. Th  is activation of type I 
receptors then phosphorylates the receptor-regulated 
Smad (R-Smad) proteins Smad2 and Smad3, which enter 
the cell nucleus together with the common-Smad (Co-
Smad), Smad4, resulting in regulation of gene trans-
cription in bone cells [36].
In bone metastasis, activin A produced by tumor cells 
acts as a stimulator of bone degradation, inhibiting osteo-
blast diﬀ  erentiation and stimulating osteoclast diﬀ  eren-
tiation [36]. Interestingly, circulating levels of activin A in 
the serum of breast or prostate cancer patients with bone 
metastases are signiﬁ  cantly higher than those of patients 
without bone metastases [37]. Th  erefore, this cytokine 
may be considered as a potential target for a more 
selective therapeutic approach in the treatment of skele-
tal metastasis. For example, diﬀ  erent groups have recently 
used a soluble form of the extracellular domain of Act 
RIIA receptor fused to the Fc fragment of a murine IgG 
(RAP-011) to show that it stimulates bone formation and 
blocks the formation of osteolytic lesions in animal 
models of myeloma and breast cancer [37,38]. A phase-
IIa, multiple-dose study is currently evaluating the safety, 
tolerability and eﬃ   cacy of the human analog of RAP-011, 
namely ACE-011 (Celgene Corporation), in patients with 
osteolytic lesions of multiple myeloma (n = 30) 
(NCT00747123). Th  ere are no ongoing clinical trials in 
breast cancer.
Endothelin-1
Th  e endothelins comprise a family of three small (21 
amino acid) peptides: ET-1, ET-2 and ET-3 [39]. Th  ey 
exert their eﬀ  ects by binding to the cell surface receptors 
ETA and ETB [39]. Endothelins are produced by diﬀ  erent 
cell types, including breast and prostate carcinoma cells 
[39]. In bone, tumor-derived ET-1 stimulates mitogenesis 
in osteoblasts, which express both ETA and ETB, and it 
decreases osteoclast activity and motility [39]. ET-1 is 
therefore involved in the formation of osteoblastic lesions 
that are frequently observed in patients with metastatic 
prostate cancer and, to a lesser extent, in metastatic 
breast cancer. For example, human ZR-75-1 breast cancer 
cells cause osteoblastic bone metastases in animals that 
are inhibited by ETA antagonist ABT-627 (atrasentan) 
[40]. Th  e mixed (ETA and ETB) inhibitor bosentan also 
inhibits murine 4T1 breast cancer bone metastases in 
vivo  [41]. Furthermore, ET-1 and ET-2 increase breast 
cancer cell migration and invasion in vitro [42]. Th  ere  is 
therefore a rationale in studying the eﬀ  ect of endothelin 
antagonists in breast cancer patients with bone 
metastases. However, no clinical trials in breast cancer 
have been conducted so far. In prostate cancer, clinical 
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clinical trials with zibotentan, a more selective inhibitor 
of ETA, in prostate cancer are currently ongoing. 
However, two of these trials have recently been stopped 
because of a lack of beneﬁ  t as of 7 February 2011 [44].
Novel targets from the bone microenvironment
TGF-β
TGF-β binds to a heteromeric complex of transmembrane 
serine/threonine kinases, the type I and type II receptors 
ALK5 and TβRII, which phosphorylate and activate the 
TGF-β-speciﬁ  c intracellular signaling mediators Smad2 
and Smad3. Th   e phosphorylated Smad2/3 complex then 
binds Smad4 and translocates to the nucleus, where it 
regulates the transcription of TGF-β target genes [45]. In 
skeletal tissue, TGF-β is a major bone-derived growth 
factor responsible for driving growth of several solid 
tumors, including breast cancer. It regulates the expres-
sion of many factors (integrin αvβ3, IL-6, IL-8, IL-11, 
MMP-1, CXCR-4, and so on) that are involved in bone 
metastasis formation [45].
Th  us, the blockade of TGF-β signaling oﬀ  ers a target 
for therapeutic intervention to decrease bone metastases. 
Several strategies designed to inhibit TGF-β signaling - 
such as dominant negative TβRII, small molecule inhi-
bitors of TβRI, antisense oligonucleotides and neutral  iz-
ing TGF-β antibodies - have been used to block experi-
mental breast cancer bone metastases [45-47]. However, 
to date, there have been no clinical trials studying the 
eﬀ  ect of a TGF-β-related therapy for breast cancer with 
bone metastases, although TGF-β inhibitors have been 
investigated for other types of cancers. Details of these 
TGF-β inhibitors in ongoing clinical trials have been 
recently reviewed [45].
By signaling through the Smad pathway, TGF-β is also 
an eﬀ   ector of epithelial-to-mesenchymal transition 
(EMT), a process known to facilitate cancer progression 
and metastasis [48]. Interestingly, exogenous BMP-7, a 
member of the TGF-β superfamily, antagonizes TGF-β 
signaling and reduces EMT in breast and prostate cancer 
cells, which leads to the inhibition of bone metastasis 
formation in animals [49,50]. In a similar vein, the 
Jagged1-Notch pathway in breast cancer cells is strongly 
upregulated by TGF-β and the pharmacological disrup-
tion of the Notch signaling pathway by the γ-secretase 
inhibitor MRK-003 blocks breast cancer bone metastasis 
formation in animals [4]. Notch stimulates EMT [48]. We 
could therefore envision that targeting the TGF-β-depen-
dent EMT pathway with BMP-7 or γ -secretase inhibitors 
could be an alternative strategy to ﬁ  ght bone metastases.
CXCL-12/CXCR-4
Chemokines can be secreted by virtually all types of cells. 
Most of the chemokines are up-regulated in the presence 
of pro-inﬂ   ammatory signals and are involved in both 
adaptive and innate immune responses, whereas a few, 
such as CXCL-12, are constitutively expressed and are 
important for normal cellular traﬃ   cking [51]. In bone, 
CXCL-12 is produced by multiple bone marrow cell 
types, including osteoblasts. Chemokines work by bind-
ing to speciﬁ  c G-protein-coupled receptors on plasma 
membranes of target cells.
Th   ere is now ample evidence that chemokines and their 
receptors play a key role in organ-speciﬁ  c cancer meta-
stasis [51]. In this respect, several chemokine receptors 
(CXCR3, CXCR4, CCR4, CCR5, and CCR7) expressed by 
breast cancer cells are associated with metastases, among 
which CXCR4 seems to be a major metastasis-regulator 
receptor [51]. CXCR4 controls the metastatic destination 
of breast cancer cells in organs (lung, liver, and bone) 
where its ligand, the chemokine CXCL-12, is produced in 
high quantity [51]. Moreover, CXCL-12 is not only 
implicated in the homing of breast cancer cells in the 
bone marrow, but also in their survival [22]. CXCL-12, by 
binding to CXCR4, activates the nonreceptor tyrosine 
kinase Src, which, in turn, stimulates the AKT cell 
survival pathway in breast cancer cells residing in the 
bone marrow [22].
Th  us, the CXCL-12/CXCR-4 axis seems to be an 
attractive therapeutic target to treat bone metastases. 
Consistent with this, the blockade of CXCR4 using anti-
bodies or a synthetic peptidic antagonist (CTCE-9908) 
reduces the formation of experimental lung and bone 
metastases caused by CXCR4-expressing breast cancer 
cells [52,53]. Data from clinical trials are, however, scant. 
A phase I/II clinical trial has determined the tolerability 
and safety proﬁ   le of repeated administration of 
CTCE-9908 in patients (n = 25) with advanced metastatic 
disease who stopped responding to standard treatments 
or for whom no curative therapy exists. Th  e clinical 
response was modest (6 patients out of 20 (30%) had 
overall stable disease) and the tolerability was good [53]. 
However, caution should be used in designing trials to 
evaluate the utility of blockade of the CXCL-12/CXCR-4 
axis. Preclinical data indicate that disruption of CXCR4 
may enhance osteoclastic bone resorption, thus making 
the bone an even more favorable site for growth of tumor 
cells [54]. As such there is theoretical concern that 
treatment of patients with CXCR4 inhibitors could lead to 
increased bone turnover causing both detrimental eﬀ  ects 
on bone health as well as increased tumor burden in bone.
Conclusion
Findings presented in this review highlight several 
molecular components acting at early and late stages 
during the development and progression of breast cancer 
bone metastases (Figure 1). Th   ese components stand as 
attractive new targets for cancer therapeutics. Th  ey  could 
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ently block the development of skeletal lesions in women 
with breast cancer.
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